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Results from a Prospective Study
Mats Remberger,1,2 Berit Sundberg2In a prospective study we determined rabbit-IgG (r-IgG) levels in serum samples before (day 0) and after (days
1 and 7) unrelated donor hematopoietic stem cell transplantation (HSCT). Most patients suffered from
a hematologic malignancy. All patients received rabbit antithymocyte globulin (ATG) as part of the condition-
ing for 2-4 days (2 mg/kg/day). We found a good correlation (r5 0.34, r5 0.42 and r5 0.46) between the
dose of ATG and serum r-IgG levels at all 3 time points. The cumulative incidence of acute graft-versus-host
disease (aGVHD) grades II-IV in patients given the 4, 6, and 8 mg/kg ATG dose was 50%, 34%, and 15%
(P5.04), respectively. In patients with r-IgG #70 mg/mL (n5 54) the cumulative incidence of grades II-IV
aGVHD was 33% compared with only 6% in those with r-IgG .70 mg/mL (n5 18), P 5.023. Low serum
levels of r-IgG seem to be a strong predictor for aGVHD grades II-IV in patients treated with Thymoglobulin
before unrelated donor HSCT.
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Antithymocyte globulin (ATG) is often used as
part of the conditioning therapy before unrelated do-
nor hematopoietic stem cell transplantation (HSCT)
to reduce the risk for graft-versus-host disease
(GVHD) and rejection [1]. We have previously retro-
spectively analyzed frozen samples collected at the day
of HSCT and at different time points thereafter, and
found a correlation between serum rabbit-IgG levels
and aGVHD [2].MATERIALS AND METHODS
We prospectively collected blood samples at
predefined time points before and after HSCT: imme-
diately before infusion of the graft (d0), 24 hours laterCenter for Allogeneic StemCell Transplantation; and 2De-
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6/j.bbmt.2009.04.013(d1), and 7 days after HSCT (d7). The samples were
allowed to clot, were centrifuged, and the serum
were collected and frozen in –20 C pending analysis.
The method for analysing rabbit-IgG (r-IgG) has pre-
viously been described in detail [2]. We analyzed only
total r-IgG, as we presently are not able to characterize
the specific ATG that binds to leukocytes (active part).
The study was approved by the ethical committee and
performed in accordance with the declaration of
Helsinki. All participating patients signed informed
consent documents.
A total of 76 patients with an unrelated donor were
included in the study. Most patients suffered from
a hematologic malignancy: 25 in first complete remis-
sion (CR1) or first chronic phase (CP1) (Table 1).There
were 45 males and 31 females, with a median age of 41
years (1-67 years). All donorswereHLA-A, -B, and -DR
identical at allele level. All patients and donors were
typed using polymerase chain reaction-sequence-spe-
cific primer (PCR-SSP) high-resolution typing for
both HLA class I and II antigens (at a 4-digit level).
Conventional myeloablative (MA) conditioning
was given to 37 patients including cyclophosphamide
(Cy, total dose 120 mg/kg) in combination with busul-
phan (Bu, total dose 16 mg/kg) (n5 21) or 12 Gy frac-
tionated total body irradiation (fTBI) (n5 16) [3].
Reduced intensity conditioning (RIC) was given to
39 patients including fludarabine (Flu; 30 mg/m2 for
5-6 days) in combination with 6 Gy fTBI and 60 mg/
Table 1. Patients Characteristics
Diagnosis
Acute myelogenous leukemia 24
Acute lymphoblastic leukemia 12
Myelodysplastic syndrome 7
Other malignancies 18
Solid tumor 3
Nonmalignant disease 12
Disease stage (early/late) 25/36
Sex (male/female) 45/31
Age 41 (1.5-67)
Donor sex (male/female) 50/26
Donor age 31 (20-49)
Conditioning
TBI-based MAC 16
Busulphan-based MAC 21
RIC 39
GVHD prophylaxis
CsA +MTX 60
Rapamycin + FKk 506 16
Stem-cell source (PBSC/BM) 60/16
Nucleated-cell dose (108/kg) 10.3 (1.6-21.1)
CD34+ cell-dose (106/kg) 7.0 (0.6-26.8)
TBI indicates total body irradiation; MAC, myeloablative conditioning;
RIC, reduced-intensity conditioning; CsA, cyclosporine A; MTX, meth-
otrexate; PBSC, peripheral blood stem cells; BM, bone marrow.
Early disease, first complete remission (CR1) or first chronic phase
(CP1); late disease; beyond CR1 or CP1.
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60 mg/kg Cy (n5 9) [6], or 42 g/m2 Treosulphan
(n5 2) [7]. All patients received rabbit ATG (Thymo-
globulin, Genzyme, Cambridge, MA) for 2-4 days
(2 mg/kg/day) with the last dose given on the day be-
fore (day –1) graft infusion [8]. Doses depended on di-
agnosis and treatment protocol. GVHD prophylaxis
consisted mainly of cyclosporine (CsA) in combination
with 4 doses of methotrexate (MTX) [9]. During the
first month, blood CsA levels were kept at 200-300
ng/mL [10]. In the absence of GVHD, CsA was dis-
continued after 6 months in patients with malignant
disease and after 18-24 month in patients with nonma-
lignant disorders. Acute GVHD and chronic GVHD
(aGVHD, cGVHD) were diagnosed on the basis of
clinical symptoms and/or biopsies (skin, liver, gastro-
intestinal tract, or oral mucosa) according to standard
criteria [11,12]. The patients were treated for grade I
aGVHD with prednisolone, starting at 2 mg/kg/day,
which was tapered after the initial response.
The probabilities of overall survival (OS) and re-
lapse-free survival (RFS) were estimated using the
method developed by Kaplan-Meier and compared
with the log-rank test. The incidence of GVHD,
treatment-related mortality (TRM), and relapse were
estimated using a nonparametric estimator of cumula-
tive incidence curves [13].RESULTS AND DISCUSSION
Four patients received a total dose of 4 mg/kg of
ATG, 46 received 6 mg/kg, and 26 patients 8 mg/kg.We found a good correlation (r5 0.34, r5 0.42, and
r5 0.46) between the dose of ATG and serum r-IgG
levels at all 3 time points (d0, d1, and d7), although
the variation was wide within each dose of ATG.How-
ever, the variation was more limited compared to the
previous study [2], which probably is because the sam-
pling in the present study was more precise. The mean
r-IgG concentration at d0, d1, and d7 for patients
given the 6 and 8 mg/kg dose of ATG was 49, 38,
and 26 mg/mL and 63, 55, and 42 mg/mL,
respectively (P \ .01), which is in accordance with
a previous study [14]. Rabbit-IgG levels were 85%
on d1 and 60% on d7 of the d0 level. The estimated
half-life of rabbit-IgG was approximately 9 days
(Figure 1A).
aGVHD grades I, II, and III-IV occurred in 20
(26%), 19 (25%), and 2 (3%) patients, respectively,
whereas 35 patients had no GVHD. A good ATG
dose-dependent effect on aGVHD was seen. The
cumulative incidence of aGVHD grades II-IV in
patients given the 4, 6, and 8 mg/kg dose was 50%,
34%, and 15% (P5 .04), respectively. This dose effect
of ATG on GVHD has previously been reported from
our center as well as by others [8,15,16].
In the previous report, we found that patients with
r-IgG levels\70 mg/mL in samples before HSCT (d0)
had a significantly higher risk for aGVHD [2]. In the
present study, this cutoff level still was a good predic-
tor for aGVHD grades II-IV. In patients with r-IgG
#70 mg/mL (n5 54) the cumulative incidence of
grades II-IV aGVHD was 33% compared with only
6% in those with r-IgG .70 mg/mL (n5 18),
P5 .023 (Figure 1B). However, no significant differ-
ences in TRM (13% versus 12% at 1 year) and OS
(66% versus 83% at 3 years, P5 .47) were seen be-
tween patients with r-IgG #70 or .70 mg/mL in the
d0 sample (Figure 1C). The main reason for this is
probably that only 2 patients developed severe (grade
III) aGVHD, and that there was no difference in
TRM between patients with no, grade I, or grade II
aGVHD in this study. ATG has also been shown to
affect cGVHD [15,17,18]. We found a weak, nonsig-
nificant, dose-dependent effect of ATG on cGVHD,
67%, 15%, and 9% in patients receiving 4, 6, and
8 mg/kg of ATG, resectively. The cumulative inci-
dence of cGVHD in patients with low (#70 mg/mL)
or high r-IgG levels at d0 was 19% and 7%, P 5 ns.
GVHD carries a graft-versus-leukemia (GVL) effect
that protects against relapse, and cGVHD probably
has the strongest antileukemic effect [19,20]. For this
reason, we also correlated r-IgG levels to relapse.
However, no effect of r-IgG levels on relapse was
found between patients with low or high r-IgG levels,
25% versus 36%, P 5 ns, respectively. Three patients
rejected their graft 125, 147, and 182 days afterHSCT,
all 3 were given RIC. We found no correlation be-
tween r-IgG levels and rejection in this material.
Figure 1. (A) Kinetics of total rabbit-IgG during the study period in pa-
tients given 3 different doses of Thymoglobulin. (B) Cumulative inci-
dence of aGVHD grades II-IV. (C) Probability of OS, depending on
serum levels of rabbit-IgG immediately before HSCT (d0).
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lymphoma. Two of these 3 patients received 8 mg/kg
and 1 received 6 mg/kg of Thymoglobulin. No corre-
lation between r-IgG levels and EBV-lymphoma was
observed.
Finally, we added the data from the previous retro-
spective study to the present prospective study. In this
combined material, including a total of 128 patients,
we found a cumulative incidence of aGVHD grades
II-IV of 9%and 41% in patients with r-IgG.70 mg/mLand \70 mg/mL immediately before HSCT (d0,
P5 .001). In the multivariate analysis, d0 r-IgG
\70 mg/mL (hazard ratio [HR] 5.05, confidence inter-
val [CI] 1.82-14.0, P5 .002), ATG dose (1.30, 1.00-
1.70, P5 .05), and conventional conditioning (2.24,
1.09-4.62, P5 .028) were associated with aGVHD
grades II-IV. Factors like patient age, stem-cell source,
disease stage, and diagnosis was not significantly asso-
ciated with aGVHD in this combined material.
Among patients with acute myelogenous leukemia
(AML) and myelodysplastic syndromes (MDS)
(n5 53), there was an increased incidence of aGVHD
(47% versus 11%, P5 .014), a trend formore cGVHD
(25% versus 14%, P5 .25), and less relapse (31% ver-
sus 51%, P5 .09) in patients with low d0 r-IgG
(\70 mg/mL) compared with those with high levels.
This study indicates that low levels of r-IgG is
a strong predictor for aGVHD grades II-IV in patients
treated with Thymoglobulin before unrelated donor
HSCT. Patients with low levels of r-IgG at d0 may
benefit from an additional dose of ATG to increase
the serum levels of r-IgG.ACKNOWLEDGMENTS
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